PT-141 (Bremelanotide) — Research Overview

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide and metabolite of Melanotan II with selective affinity for melanocortin receptors, particularly MC3R and MC4R. Unlike many peptides that operate through peripheral mechanisms, PT-141 has been studied for its ability to penetrate the blood-brain barrier due to its molecular size and lipophilic properties, enabling direct central nervous system effects that have made it a useful research tool for investigating central melanocortin pathways and their downstream physiological influence. Laboratory studies have examined its interactions with dopaminergic pathways, nitric oxide synthase activity in neural circuits, and hypothalamic neuron activation. Available from 4-LD in 10mg lyophilized form, PT-141 is produced under quality-controlled conditions exclusively for qualified researchers and laboratory professionals conducting in-vitro and controlled research applications.

Areas of Active Research

PT-141 has been studied across several active research areas. In central nervous system research, rodent and primate models have examined its dose-dependent activation of hypothalamic neurons and its influence on c-Fos expression in brain regions associated with autonomic function, with studies documenting rapid CNS penetration and sustained receptor binding following administration. In behavioral neuroscience research, animal studies have investigated its effects on motivation and reward pathways through indirect dopamine release modulation in the nucleus accumbens, as well as its influence on social behavior and social interaction models. In autonomic nervous system research, studies in canine and rodent models have examined its effects on cardiovascular regulation including blood pressure and heart rate responses through central sympathetic activation, as well as its influence on thermoregulatory pathways through hypothalamic MC4R activation. In receptor binding research, in-vitro assays have characterized its binding affinity and selectivity profile across the melanocortin receptor subtypes, with findings consistently demonstrating preferential activity at MC3R and MC4R over other receptor subtypes. All findings referenced are from preclinical and in-vitro studies. This product is intended solely for laboratory research by qualified professionals and is not for human or animal consumption. 4-LD makes no therapeutic claims regarding this compound.